Hims Daily (Jul 8, 2025)

200% tariffs on pharma coming soon?! 🤯

Jul 08, 2025

Today’s Hims Daily is brought to you by … Godel Terminal

People have tried to build a “Bloomberg killer” for years. Godel might actually pull it off. They’re just getting started, but what they’ve already built delivers 90% of Bloomberg’s functionality at less than 10% of the price. It’s a full trading terminal for $80/month.

We use it daily to track short interest, institutional ownership, analyst ratings, and more. If you want access to the data powering Hims House, this is it. Sign up today to lock in lifetime access for $80/mo. First month just $60 if you click here to sign up 🔥

Stock Price: $48.97

Today: +$0.56 (+1.15%)
YTD: +$24.79 (+102.54%)
Q3: -$0.88 (-1.76%)

🚨 Hims just had its BIGGEST WEEK of the quarter. Our latest Hims Data Tracker breaks it all down… Upgrade to paid for access!

What’s Happening

$50+ breakout fades. HIMS surged to $50.82 in the early afternoon, but slumped for the rest of the day and finished at $48.97.
- Volume was just 30M.
Trump floated 200% tariffs on pharma imports with a one-year grace period. Shares initially reacted favorably to the announcement, but ultimately the rest of the market dragged Hims down with it.
Hims recently raised the starting price of its personalized GLP-1s back to $199/month, the same level it was before Dec 20, 2024. It had been $165/month since that date.
- The $199 rate applies to the 12-month plan paid upfront in full.
Medicaid reform adds another macro layer. Treasury Secretary Scott Bessent tweeted that the “Big Beautiful Bill” will tighten Medicaid eligibility for able-bodied adults, and cited recent polls showing strong voter support. If reforms shift patients away from traditional programs, domestic cash-pay providers like HIMS could benefit long-term.
Legal risk in focus, but may be fading. Morgan Stanley’s note yesterday reiterated caution, but with each day that passes it becomes a little less likely that Novo will sue. Kalshi suggests the odds of a Novo lawsuit have dropped from 48% to 31% over the past week.
Chart still coiling. HIMS is now basing between $47 support and $50.80 VWAP resistance, with bulls eyeing a breakout above $51–52 to target the low $60s gap.
Narrative shifting from Novo to new growth. Community chatter has turned to upcoming menopause/TRT rollouts and Hims’ AI roadmap. Meanwhile, bears are pointing to a slowing “core” business, analyst downgrades, and FY25 revenue concerns.